Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — Investor Presentation (July 2023)
21 slides from Alaunos Therapeutics's investor presentation, July 2023
Slide 1: Attacking Solid Tumors with Novel TCR-T Cell Therapies
Attacking Solid Tumors with Novel TCR-T Cell Therapies July 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will
Slide 3: Delivering the Promise: Revolutionizing Solid Cancer Treatment with TCR-T
Delivering the Promise: Revolutionizing Solid Cancer Treatment with TCR-T 2022 2023 2024+ Significant Accomplishments Anticipated Milestones Building for the Future First TCR-T objective clinical Phase 2 readiness Pivotal clinical trials response in solid tumors Expand TCR library to 15 Combination
Slide 4: Robust Solid Tumor Program Pipeline with Multiple Near-Term Inflection Points
Robust Solid Tumor Program Pipeline with Multiple Near-Term Inflection Points PROGRAM TARGETS INDICATION PRECLINICAL IND-ENABLING PHASE 1 PHASE 2 KRAS Lung G12D & G12V Colon/Rectum Library TCR-T Cell TP53 Endometrium R175H, R248W, Therapy Pancreas R273C & Y220C Ovary EGFR E746-A750del Bile Duct mbIL
Slide 5: Driver Mutations are Ideal Targets for TCR-T Cells to Treat Solid Tumors
Driver Mutations are Ideal Targets for TCR-T Cells to Treat Solid Tumors Target Examples Key Advantages Key Disadvantages • Drives cancer • Highly expressed targets Driver Mutations Mutated EGFR, KRAS or TP53 • Single targets • Not on normal tissue • Large addressable market • Small addressable mark
Slide 6: Alaunos Evaluating TCR-T Against the Most Frequently Mutated Genes in Solid Tumors
Alaunos Evaluating TCR-T Against the Most Frequently Mutated Genes in Solid Tumors: KRAS, TP53, EGFR Nearly 2 million solid tumors cases diagnosed in United States annually Limited approved drugs for these high value targets These six indications represent ~600,000 new cases per year 6 Source: Most
Slide 7: Confirmed Responses from Leading Academic Institutions Corroborate Targeting Driver Mutations
Confirmed Responses from Leading Academic Institutions Corroborate Targeting Driver Mutations with TCR-T Cells Greater than 70% tumor reduction of metastatic pancreatic 55% tumor reduction of metastatic breast cancer six cancer six months after infusion of KRAS-G12D and HLA- months after infusion of
Slide 8: Differentiated Approach to Convert Natural T-Cell Responses into TCR-T Cell Therapy
Differentiated Approach to Convert Natural T-Cell Responses into TCR-T Cell Therapy for a Broad Patient Population TCR Source TCR Library Manufacture TCR-T Cell Therapy Natural TIL 1. Isolate Reactive Autologous TCR-T Response to TCR to Target A Cells Reactive to Target A Target A 2. Make Sleeping B
Slide 9: Industry Leading TCR Library Captures Both High Frequency Mutations and HLA Types
Industry Leading TCR Library Captures Both High Frequency Mutations and HLA Types In over 700 patients screened, 15% match rate to a TCR in our library Two-pronged library expansion strategy: 1. Add more HLAs to existing mutations 2. Add more mutations to KRAS, TP53, EGFR Our TCR library contains mu
Slide 10: Non-viral Sleeping Beauty Platform Ideal for Manufacturing TCR-T Cells
Non-viral Sleeping Beauty Platform Ideal for Manufacturing TCR- T Cells without Complexity of Gene Editing • Efficient, essentially random integration without complexity of gene editing or viral approaches • Rapid, cost-effective manufacturing • Flexible approach to add TCRs; attractive choice for l
Slide 11: TCR-T Cells Recognize KRAS, TP53, EGFR Mutations and Kill Solid Tumor Cells
TCR-T Cells Recognize KRAS, TP53, EGFR Mutations and Kill Solid Tumor Cells Powerful TCRs: Naturally-occurring, high avidity TCRs recognize low levels of neoantigens No off-target toxicity observed: Specificity for the mutation with negligible recognition of wild type sequences Tumor killing: Recogn
Slide 12: TCR-T Cell Products are Manufactured with a TCR Matched to Each Patient's Tumor Mutation
TCR-T Cell Products are Manufactured with a TCR Matched to Each Patient’s Tumor Mutation and HLA Type Screening 1 2 Selection of TCR from Library Infusion 7 for Manufacturing Formulation & Cryopreservation 6 3 Peripheral Blood Leukapheresis 5 4 Sleeping Beauty Transposition of TCR TCR Expression & E
Slide 13: Universal, In-House Manufacturing Platform Delivers High Quality TCR-T Cell Products
Universal, In-House Manufacturing Platform Delivers High Quality TCR-T Cell Products Ongoing Process Optimization Patient 1 Patient 2 Patient 3 Mutation KRAS-G12D TP53-R175H KRAS-G12V Automation and closed process Indication Lung Colorectal Pancreatic steps to increase throughput Dose Level One Two
Slide 14: First-in-Human TCR-T Clinical Trial Actively Enrolling with Innovative Library Approach
First-in-Human TCR-T Clinical Trial Actively Enrolling with Innovative Library Approach • Defines safety and dose with any TCR and any indication Phase 1 • Enrolling in one of three dose cohorts: 5, 40 and 100 billion TCR-T cells • Defines efficacy at recommended dose with any TCR in library Phase 2
Slide 15: First-in-Human Confirmed Response in Solid Tumors by Sleeping Beauty TCR-T Cell Therapy
First-in-Human Confirmed Response in Solid Tumors by Sleeping Beauty TCR-T Cell Therapy SAFETY PERSISTENCE EFFICACY Manageable safety profiles Persisting TCR-T cells First TCR-T cell response in in first two dose levels (20%-30%) in blood checkpoint inhibitor refractory NSCLC No DLTs TCR-T cells tra
Slide 16: Patient 1 Showed Durable, Complete Resolution of NSCLC Lesion Through Six Months
Patient 1 Showed Durable, Complete Resolution of NSCLC Lesion Through Six Months Insert Image Here Insert Image Here TCR-T cells from biopsy were grown in lab before analysis; No biopsy was 0 6available from Pt-02. 12 24 Baseline Week 6 Week 12 Week 24 • Patient 1 had multiple lines of prior therapy
Slide 17: TCR-T Cells Persist in Blood and Traffic to Tumor Microenvironment
TCR-T Cells Persist in Blood and Traffic to Tumor Microenvironment TCR-T Cell Expansion and Persistence in Blood Patient 1: Patient 3: Seven-Month Tumor Biopsy Six-Week Tumor Biopsy TCR-T Cells in Blood (%) 100 Pt-01 80 Pt-02 TCR-T TCR-T Pt-03 6.1% 5.6% 60 TCR-T TCR-T 40 20 0 0 30 60 90 120 150 180
Slide 18: Next-Generation TCR-T Efforts Aim to Deepen Clinical Responses
Next-Generation TCR-T Efforts Aim to Deepen Clinical Responses Augmenting TCR-T Survival via Combine TCR-T and Immune Multiple TCRs Infused into Co-Expression of mbIL-15 Checkpoint Inhibitors the Same Patient Regeneration of effector Reinvigorate TCR-T cells in the Attack multiple targets on the tum
Slide 19: hunTR Expands TCR Library, Increases Addressable Market and Enables Multiplexed TCR-T
hunTR® Expands TCR Library, Increases Addressable Market and Enables Multiplexed TCR-T Cell Therapy 2024+ Add new HLAs to existing mutations and add 40+ more key mutations within EGFR, KRAS, TP53 TCRs 2023 Matching data from clinical efforts inform which 15 Potential Patients per Year HLA/mutation c
Slide 20: Experienced Management Team
Experienced Management Team Kevin S. Boyle, Sr. Melinda Lackey Chief Executive Officer SVP Legal Drew Deniger, PhD Abhishek Srivastava, PhD Mike Wong VP Research & Development VP Technical Operations VP Finance Melinda Lackey 20
Slide 21: 2023 Milestones Designed to Cement Our Leadership Position in TCR-T Cell Therapy
2023 Milestones Designed to Cement Our Leadership Position in TCR- T Cell Therapy for the Treatment of Solid Tumors Advance TCR-T Optimize New IND for Expand TCR Library to 15 TCRs Library trial to manufacturing mbIL-15 TCR-T Phase 2 process towards Translational assessment- commercial driven next-g
Alaunos Therapeutics — Investor Presentation (July 2023) on 6ix